Corteva (NYSE:CTVA) on Monday was upgraded to Buy from a previous investment rating of Hold by analysts at Argus Research.

Fintel reports that on March 31, 2025, Argus Research upgraded their outlook for Corteva (NYSE:CTVA) from Hold to Buy.

In a report released yesterday, Bill Selesky from Argus Research maintained a Hold rating on Air Products and Chemicals (APD – Research ...

Fintel reports that on April 4, 2025, Argus Research downgraded their outlook for Biogen (BIT:1BIIB) from Buy to Hold. As of April 2, 2025, the average one-year price target for Biogen is €185. ...

Fintel reports that on April 4, 2025, Argus Research downgraded their outlook for Biogen (WBAG:BIIB) from Buy to Hold. There are 1,721 funds or institutions reporting positions in Biogen.

Argus Research analyst Marie Ferguson maintained a Hold rating on Centerpoint Energy (CNP – Research Report) yesterday. The company’s shares ...

Strategic M&A Model: In recent years, GMGI has expanded its operations through strategic mergers and acquisitions (M&A). In many of these instances, GMGI has acquired companies that were initially ...

Kevin is the Chief Compliance Officer for the Argus Research Group. His responsibilities include ensuring that the firm is SEC compliant and adheres to all rules and regulations. He has over ...

Investing.com -- Argus Research downgraded Lululemon Athletica (NASDAQ:LULU) to "hold" from "buy," citing concerns over an aging product line, U.S. tariffs, and intensifying competition from rivals ...

Corteva (NYSE:CTVA) on Monday was upgraded to Buy from a previous investment rating of Hold by analysts at Argus Research. They said the maker of farm chemicals and seeds offers improved demand ...